Biotech Values

[genisi]

I thought that Tysabri's introduction at a 2 times higher price started the aggressive price hikes trend. Now that other MS therapies have closed much of the pricing gap, I wonder if BIIB wants to keep Tysabri's price on top as and will raise again (last time was June 2008). I'm not assuming no additional price increases for the remainder of 2009 for Copaxone as TEVA typically increases twice a year.

Note that in Europe and the international markets, most of Copaxone's growth was driven by volume increase not price.